SCHEMBL31518

SCHEMBL31518

CC(=O)N1CCN(C(=O)c2ccc3nc(C)c(-c4ccccc4)n3c2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 0.72
SLC6A7 Q99884 2/20 0.45
MKNK1 Q9BUB5 3/20 0.44
MKNK2 Q9HBH9 3/20 0.44
EIF4E P06730 1/20 0.44
POLB P06746 2/20 0.44
AKT1 P31749 2/20 0.44
AKT2 P31751 2/20 0.44
SLC2A1 P11166 1/20 0.43
NCF1 P14598 1/20 0.43
GBA1 P04062 1/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 2/20 0.42
LMNA P02545 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ACACB O00763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15071152 0.93 F2RL1 (0.75) F2RL1SLC6A7MKNK1MKNK2POLB
SCHEMBL15071100 0.89 F2RL1 (0.77) F2RL1SLC6A7AKT1AKT2GBA1
SCHEMBL15071143 0.87 F2RL1 (0.74) F2RL1SLC6A7MKNK1MKNK2POLB
SCHEMBL15050009 0.87 F2RL1 (0.68) F2RL1SLC6A7MKNK1MKNK2EIF4E
SCHEMBL31526 0.87 F2RL1 (0.90) F2RL1SLC2A1HPGDSMN1; SMN2ACACB
SCHEMBL15071160 0.87 F2RL1 (0.67) F2RL1SLC6A7POLBAKT1AKT2
Hydrochloric Acid SCHEMBL15049976 0.86 F2RL1 (0.67) F2RL1SLC6A7MKNK1MKNK2EIF4E
SCHEMBL15071158 0.86 F2RL1 (0.73) F2RL1ALDH1A1HPGDKDM4ELMNA
SCHEMBL15071154 0.86 F2RL1 (0.66) F2RL1SLC6A7AKT1AKT2SLC2A1
SCHEMBL15049974 0.85 F2RL1 (0.65) F2RL1POLBAKT1GBA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed
WO-2012026765-A2 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME (주)네오팜 (KR) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME F2RL1, F2R, FPR2 F2RL1 1/4885SLC6A7 4680/4885MKNK1 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.